Dazodalibep improved Sjögren’s disease by Week 4. Can Amgen beat Novartis to a new treatment market?
Amgen’s dazodalibep has met the primary endpoint in the Phase 3 OASIZ 301 study, improving systemic Sjögren’s disease activity as early as Week 4 and sustaining the benefit through Week 48. The result is a major step in a disease with no FDA-approved systemic treatment specifically for Sjögren’s, but Amgen has not yet disclosed the